<?xml version="1.0" encoding="utf-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1996-02-01" modified="2020-10-07" version="207">
<accession>P47712</accession>
<accession>B1AKG4</accession>
<accession>Q29R80</accession>
<name>PA24A_HUMAN</name>
<protein>
<recommendedName>
<fullName>Cytosolic phospholipase A2</fullName>
<shortName>cPLA2</shortName>
</recommendedName>
<alternativeName>
<fullName>Phospholipase A2 group IVA</fullName>
</alternativeName>
<domain>
<recommendedName>
<fullName>Phospholipase A2</fullName>
<ecNumber evidence="15 18 19 21 23 30">3.1.1.4</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Phosphatidylcholine 2-acylhydrolase</fullName>
</alternativeName>
</domain>
<domain>
<recommendedName>
<fullName>Lysophospholipase</fullName>
<ecNumber evidence="18 21">3.1.1.5</ecNumber>
</recommendedName>
</domain>
</protein>
<gene>
<name type="primary">PLA2G4A</name>
<name type="synonym">CPLA2</name>
<name type="synonym">PLA2G4</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1991" name="Cell" volume="65" first="1043" last="1051">
<title>A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP.</title>
<authorList>
<person name="Clark J.D."/>
<person name="Lin L.-L."/>
<person name="Kriz R.W."/>
<person name="Ramesha C.S."/>
<person name="Sultzman L.A."/>
<person name="Lin A.Y."/>
<person name="Milona N."/>
<person name="Knopf J.L."/>
</authorList>
<dbReference type="PubMed" id="1904318"/>
<dbReference type="DOI" id="10.1016/0092-8674(91)90556-e"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA]</scope>
<scope>PARTIAL PROTEIN SEQUENCE</scope>
<scope>VARIANT LYS-651</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1991" name="J. Biol. Chem." volume="266" first="14850" last="14853">
<title>Molecular cloning and expression of human Ca(2+)-sensitive cytosolic phospholipase A2.</title>
<authorList>
<person name="Sharp J."/>
<person name="White D."/>
<person name="Chiou G."/>
<person name="Goodson T."/>
<person name="Gamboa G."/>
<person name="McClure D."/>
<person name="Burgett S."/>
<person name="Hoskins J."/>
<person name="Skatrud P."/>
<person name="Sportsman J."/>
<person name="Becker G."/>
<person name="Kang L."/>
<person name="Roberts E."/>
<person name="Kramer R."/>
</authorList>
<dbReference type="PubMed" id="1869522"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA]</scope>
<scope>VARIANT LYS-651</scope>
</reference>
<reference key="3">
<citation type="submission" date="2004-02" db="EMBL/GenBank/DDBJ databases">
<authorList>
<consortium name="NIEHS SNPs program"/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANTS ILE-224 AND LYS-651</scope>
</reference>
<reference key="4">
<citation type="journal article" date="2006" name="Nature" volume="441" first="315" last="321">
<title>The DNA sequence and biological annotation of human chromosome 1.</title>
<authorList>
<person name="Gregory S.G."/>
<person name="Barlow K.F."/>
<person name="McLay K.E."/>
<person name="Kaul R."/>
<person name="Swarbreck D."/>
<person name="Dunham A."/>
<person name="Scott C.E."/>
<person name="Howe K.L."/>
<person name="Woodfine K."/>
<person name="Spencer C.C.A."/>
<person name="Jones M.C."/>
<person name="Gillson C."/>
<person name="Searle S."/>
<person name="Zhou Y."/>
<person name="Kokocinski F."/>
<person name="McDonald L."/>
<person name="Evans R."/>
<person name="Phillips K."/>
<person name="Atkinson A."/>
<person name="Cooper R."/>
<person name="Jones C."/>
<person name="Hall R.E."/>
<person name="Andrews T.D."/>
<person name="Lloyd C."/>
<person name="Ainscough R."/>
<person name="Almeida J.P."/>
<person name="Ambrose K.D."/>
<person name="Anderson F."/>
<person name="Andrew R.W."/>
<person name="Ashwell R.I.S."/>
<person name="Aubin K."/>
<person name="Babbage A.K."/>
<person name="Bagguley C.L."/>
<person name="Bailey J."/>
<person name="Beasley H."/>
<person name="Bethel G."/>
<person name="Bird C.P."/>
<person name="Bray-Allen S."/>
<person name="Brown J.Y."/>
<person name="Brown A.J."/>
<person name="Buckley D."/>
<person name="Burton J."/>
<person name="Bye J."/>
<person name="Carder C."/>
<person name="Chapman J.C."/>
<person name="Clark S.Y."/>
<person name="Clarke G."/>
<person name="Clee C."/>
<person name="Cobley V."/>
<person name="Collier R.E."/>
<person name="Corby N."/>
<person name="Coville G.J."/>
<person name="Davies J."/>
<person name="Deadman R."/>
<person name="Dunn M."/>
<person name="Earthrowl M."/>
<person name="Ellington A.G."/>
<person name="Errington H."/>
<person name="Frankish A."/>
<person name="Frankland J."/>
<person name="French L."/>
<person name="Garner P."/>
<person name="Garnett J."/>
<person name="Gay L."/>
<person name="Ghori M.R.J."/>
<person name="Gibson R."/>
<person name="Gilby L.M."/>
<person name="Gillett W."/>
<person name="Glithero R.J."/>
<person name="Grafham D.V."/>
<person name="Griffiths C."/>
<person name="Griffiths-Jones S."/>
<person name="Grocock R."/>
<person name="Hammond S."/>
<person name="Harrison E.S.I."/>
<person name="Hart E."/>
<person name="Haugen E."/>
<person name="Heath P.D."/>
<person name="Holmes S."/>
<person name="Holt K."/>
<person name="Howden P.J."/>
<person name="Hunt A.R."/>
<person name="Hunt S.E."/>
<person name="Hunter G."/>
<person name="Isherwood J."/>
<person name="James R."/>
<person name="Johnson C."/>
<person name="Johnson D."/>
<person name="Joy A."/>
<person name="Kay M."/>
<person name="Kershaw J.K."/>
<person name="Kibukawa M."/>
<person name="Kimberley A.M."/>
<person name="King A."/>
<person name="Knights A.J."/>
<person name="Lad H."/>
<person name="Laird G."/>
<person name="Lawlor S."/>
<person name="Leongamornlert D.A."/>
<person name="Lloyd D.M."/>
<person name="Loveland J."/>
<person name="Lovell J."/>
<person name="Lush M.J."/>
<person name="Lyne R."/>
<person name="Martin S."/>
<person name="Mashreghi-Mohammadi M."/>
<person name="Matthews L."/>
<person name="Matthews N.S.W."/>
<person name="McLaren S."/>
<person name="Milne S."/>
<person name="Mistry S."/>
<person name="Moore M.J.F."/>
<person name="Nickerson T."/>
<person name="O'Dell C.N."/>
<person name="Oliver K."/>
<person name="Palmeiri A."/>
<person name="Palmer S.A."/>
<person name="Parker A."/>
<person name="Patel D."/>
<person name="Pearce A.V."/>
<person name="Peck A.I."/>
<person name="Pelan S."/>
<person name="Phelps K."/>
<person name="Phillimore B.J."/>
<person name="Plumb R."/>
<person name="Rajan J."/>
<person name="Raymond C."/>
<person name="Rouse G."/>
<person name="Saenphimmachak C."/>
<person name="Sehra H.K."/>
<person name="Sheridan E."/>
<person name="Shownkeen R."/>
<person name="Sims S."/>
<person name="Skuce C.D."/>
<person name="Smith M."/>
<person name="Steward C."/>
<person name="Subramanian S."/>
<person name="Sycamore N."/>
<person name="Tracey A."/>
<person name="Tromans A."/>
<person name="Van Helmond Z."/>
<person name="Wall M."/>
<person name="Wallis J.M."/>
<person name="White S."/>
<person name="Whitehead S.L."/>
<person name="Wilkinson J.E."/>
<person name="Willey D.L."/>
<person name="Williams H."/>
<person name="Wilming L."/>
<person name="Wray P.W."/>
<person name="Wu Z."/>
<person name="Coulson A."/>
<person name="Vaudin M."/>
<person name="Sulston J.E."/>
<person name="Durbin R.M."/>
<person name="Hubbard T."/>
<person name="Wooster R."/>
<person name="Dunham I."/>
<person name="Carter N.P."/>
<person name="McVean G."/>
<person name="Ross M.T."/>
<person name="Harrow J."/>
<person name="Olson M.V."/>
<person name="Beck S."/>
<person name="Rogers J."/>
<person name="Bentley D.R."/>
</authorList>
<dbReference type="PubMed" id="16710414"/>
<dbReference type="DOI" id="10.1038/nature04727"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="5">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]</scope>
<scope>VARIANT LYS-651</scope>
</reference>
<reference key="6">
<citation type="journal article" date="1993" name="Cell" volume="72" first="269" last="278">
<title>cPLA2 is phosphorylated and activated by MAP kinase.</title>
<authorList>
<person name="Lin L.-L."/>
<person name="Wartmann M."/>
<person name="Lin A.Y."/>
<person name="Knopf J.L."/>
<person name="Seth A."/>
<person name="Davis R.J."/>
</authorList>
<dbReference type="PubMed" id="8381049"/>
<dbReference type="DOI" id="10.1016/0092-8674(93)90666-e"/>
</citation>
<scope>MUTAGENESIS OF SER-505</scope>
<scope>PHOSPHORYLATION AT SER-505</scope>
<scope>ACTIVITY REGULATION</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1994" name="J. Biol. Chem." volume="269" first="23250" last="23254">
<title>Serine 228 is essential for catalytic activities of 85-kDa cytosolic phospholipase A2.</title>
<authorList>
<person name="Sharp J.D."/>
<person name="Pickard R.T."/>
<person name="Chiou X.G."/>
<person name="Manetta J.V."/>
<person name="Kovacevic S."/>
<person name="Miller J.R."/>
<person name="Varshavsky A.D."/>
<person name="Roberts E.F."/>
<person name="Strifler B.A."/>
<person name="Brems D.N."/>
<person name="Kramer R.M."/>
</authorList>
<dbReference type="PubMed" id="8083230"/>
</citation>
<scope>ACTIVE SITE</scope>
<scope>MUTAGENESIS OF CYS-139; CYS-141; CYS-151; SER-195; SER-215; CYS-220; SER-228; CYS-324; CYS-331; SER-577; CYS-620; CYS-634 AND CYS-726</scope>
<scope>BIOPHYSICOCHEMICAL PROPERTIES</scope>
</reference>
<reference key="8">
<citation type="journal article" date="1995" name="Biochemistry" volume="34" first="7807" last="7818">
<title>Multiple enzymatic activities of the human cytosolic 85-kDa phospholipase A2: hydrolytic reactions and acyl transfer to glycerol.</title>
<authorList>
<person name="Hanel A.M."/>
<person name="Gelb M.H."/>
</authorList>
<dbReference type="PubMed" id="7794891"/>
<dbReference type="DOI" id="10.1021/bi00024a004"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="9">
<citation type="journal article" date="1996" name="Biochemistry" volume="35" first="3712" last="3721">
<title>Functional identification of the active-site nucleophile of the human 85-kDa cytosolic phospholipase A2.</title>
<authorList>
<person name="Huang Z."/>
<person name="Payette P."/>
<person name="Abdullah K."/>
<person name="Cromlish W.A."/>
<person name="Kennedy B.P."/>
</authorList>
<dbReference type="PubMed" id="8619991"/>
<dbReference type="DOI" id="10.1021/bi952541k"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ACTIVE SITE</scope>
<scope>MUTAGENESIS OF SER-228</scope>
</reference>
<reference key="10">
<citation type="journal article" date="1996" name="J. Biol. Chem." volume="271" first="19225" last="19231">
<title>Identification of essential residues for the catalytic function of 85-kDa cytosolic phospholipase A2. Probing the role of histidine, aspartic acid, cysteine, and arginine.</title>
<authorList>
<person name="Pickard R.T."/>
<person name="Chiou X.G."/>
<person name="Strifler B.A."/>
<person name="DeFelippis M.R."/>
<person name="Hyslop P.A."/>
<person name="Tebbe A.L."/>
<person name="Yee Y.K."/>
<person name="Reynolds L.J."/>
<person name="Dennis E.A."/>
<person name="Kramer R.M."/>
<person name="Sharp J.D."/>
</authorList>
<dbReference type="PubMed" id="8702602"/>
<dbReference type="DOI" id="10.1074/jbc.271.32.19225"/>
</citation>
<scope>FUNCTION</scope>
<scope>ACTIVE SITE</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>MUTAGENESIS OF ARG-200; SER-228 AND ASP-549</scope>
</reference>
<reference key="11">
<citation type="journal article" date="1998" name="Biochem. J." volume="329" first="369" last="372">
<title>Inhibition of human cytosolic phospholipase A2 by human annexin V.</title>
<authorList>
<person name="Buckland A.G."/>
<person name="Wilton D.C."/>
</authorList>
<dbReference type="PubMed" id="9425121"/>
<dbReference type="DOI" id="10.1042/bj3290369"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ACTIVITY REGULATION</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1998" name="J. Biol. Chem." volume="273" first="4449" last="4458">
<title>Identification of the phosphorylation sites of cytosolic phospholipase A2 in agonist-stimulated human platelets and HeLa cells.</title>
<authorList>
<person name="Boersch-Haubold A.G."/>
<person name="Bartoli F."/>
<person name="Asselin J."/>
<person name="Dudler T."/>
<person name="Kramer R.M."/>
<person name="Apitz-Castro R."/>
<person name="Watson S.P."/>
<person name="Gelb M.H."/>
</authorList>
<dbReference type="PubMed" id="9468497"/>
<dbReference type="DOI" id="10.1074/jbc.273.8.4449"/>
</citation>
<scope>PHOSPHORYLATION AT SER-505 AND SER-727</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1999" name="J. Biol. Chem." volume="274" first="17063" last="17067">
<title>Molecular characterization of cytosolic phospholipase A2-beta.</title>
<authorList>
<person name="Song C."/>
<person name="Chang X.J."/>
<person name="Bean K.M."/>
<person name="Proia M.S."/>
<person name="Knopf J.L."/>
<person name="Kriz R.W."/>
</authorList>
<dbReference type="PubMed" id="10358058"/>
<dbReference type="DOI" id="10.1074/jbc.274.24.17063"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2001" name="J. Biol. Chem." volume="276" first="30150" last="30160">
<title>Intracellular calcium signals regulating cytosolic phospholipase A2 translocation to internal membranes.</title>
<authorList>
<person name="Evans J.H."/>
<person name="Spencer D.M."/>
<person name="Zweifach A."/>
<person name="Leslie C.C."/>
</authorList>
<dbReference type="PubMed" id="11375391"/>
<dbReference type="DOI" id="10.1074/jbc.m100943200"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>DOMAIN</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2001" name="Mol. Cell. Biol." volume="21" first="4470" last="4481">
<title>PLIP, a novel splice variant of Tip60, interacts with group IV cytosolic phospholipase A(2), induces apoptosis, and potentiates prostaglandin production.</title>
<authorList>
<person name="Sheridan A.M."/>
<person name="Force T."/>
<person name="Yoon H.J."/>
<person name="O'Leary E."/>
<person name="Choukroun G."/>
<person name="Taheri M.R."/>
<person name="Bonventre J.V."/>
</authorList>
<dbReference type="PubMed" id="11416127"/>
<dbReference type="DOI" id="10.1128/mcb.21.14.4470-4481.2001"/>
</citation>
<scope>INTERACTION WITH KAT5</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="23842" last="23850">
<title>Essential Ca(2+)-independent role of the group IVA cytosolic phospholipase A(2) C2 domain for interfacial activity.</title>
<authorList>
<person name="Six D.A."/>
<person name="Dennis E.A."/>
</authorList>
<dbReference type="PubMed" id="12672805"/>
<dbReference type="DOI" id="10.1074/jbc.m301386200"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ACTIVITY REGULATION</scope>
<scope>MUTAGENESIS OF ASP-43; SER-437; SER-454; LYS-488; SER-505; LYS-541; LYS-543; LYS-544 AND SER-727</scope>
<scope>DOMAIN</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="12890" last="12897">
<title>Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A2, cPLA2delta, induced in psoriatic skin.</title>
<authorList>
<person name="Chiba H."/>
<person name="Michibata H."/>
<person name="Wakimoto K."/>
<person name="Seishima M."/>
<person name="Kawasaki S."/>
<person name="Okubo K."/>
<person name="Mitsui H."/>
<person name="Torii H."/>
<person name="Imai Y."/>
</authorList>
<dbReference type="PubMed" id="14709560"/>
<dbReference type="DOI" id="10.1074/jbc.m305801200"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2006" name="Cell" volume="127" first="635" last="648">
<title>Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
<person name="Gnad F."/>
<person name="Macek B."/>
<person name="Kumar C."/>
<person name="Mortensen P."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="17081983"/>
<dbReference type="DOI" id="10.1016/j.cell.2006.09.026"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="19">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="16615" last="16624">
<title>Identification of the expressed form of human cytosolic phospholipase A2beta (cPLA2beta): cPLA2beta3 is a novel variant localized to mitochondria and early endosomes.</title>
<authorList>
<person name="Ghosh M."/>
<person name="Loper R."/>
<person name="Gelb M.H."/>
<person name="Leslie C.C."/>
</authorList>
<dbReference type="PubMed" id="16617059"/>
<dbReference type="DOI" id="10.1074/jbc.m601770200"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2006" name="Nat. Biotechnol." volume="24" first="1285" last="1292">
<title>A probability-based approach for high-throughput protein phosphorylation analysis and site localization.</title>
<authorList>
<person name="Beausoleil S.A."/>
<person name="Villen J."/>
<person name="Gerber S.A."/>
<person name="Rush J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="16964243"/>
<dbReference type="DOI" id="10.1038/nbt1240"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="21">
<citation type="journal article" date="2007" name="J. Biol. Chem." volume="282" first="20467" last="20474">
<title>Ceramide-1-phosphate binds group IVA cytosolic phospholipase a2 via a novel site in the C2 domain.</title>
<authorList>
<person name="Stahelin R.V."/>
<person name="Subramanian P."/>
<person name="Vora M."/>
<person name="Cho W."/>
<person name="Chalfant C.E."/>
</authorList>
<dbReference type="PubMed" id="17472963"/>
<dbReference type="DOI" id="10.1074/jbc.m701396200"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ACTIVITY REGULATION</scope>
<scope>MUTAGENESIS OF 57-ARG--ARG-59</scope>
<scope>BIOPHYSICOCHEMICAL PROPERTIES</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2008" name="J. Proteome Res." volume="7" first="526" last="534">
<title>Phosphoproteome of resting human platelets.</title>
<authorList>
<person name="Zahedi R.P."/>
<person name="Lewandrowski U."/>
<person name="Wiesner J."/>
<person name="Wortelkamp S."/>
<person name="Moebius J."/>
<person name="Schuetz C."/>
<person name="Walter U."/>
<person name="Gambaryan S."/>
<person name="Sickmann A."/>
</authorList>
<dbReference type="PubMed" id="18088087"/>
<dbReference type="DOI" id="10.1021/pr0704130"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Platelet</tissue>
</source>
</reference>
<reference key="23">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-268; SER-437; SER-727 AND SER-729</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="24">
<citation type="journal article" date="2010" name="Sci. Signal." volume="3" first="RA3" last="RA3">
<title>Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Vermeulen M."/>
<person name="Santamaria A."/>
<person name="Kumar C."/>
<person name="Miller M.L."/>
<person name="Jensen L.J."/>
<person name="Gnad F."/>
<person name="Cox J."/>
<person name="Jensen T.S."/>
<person name="Nigg E.A."/>
<person name="Brunak S."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="20068231"/>
<dbReference type="DOI" id="10.1126/scisignal.2000475"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-268; SER-437 AND SER-729</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="25">
<citation type="journal article" date="2011" name="BMC Syst. Biol." volume="5" first="17" last="17">
<title>Initial characterization of the human central proteome.</title>
<authorList>
<person name="Burkard T.R."/>
<person name="Planyavsky M."/>
<person name="Kaupe I."/>
<person name="Breitwieser F.P."/>
<person name="Buerckstuemmer T."/>
<person name="Bennett K.L."/>
<person name="Superti-Furga G."/>
<person name="Colinge J."/>
</authorList>
<dbReference type="PubMed" id="21269460"/>
<dbReference type="DOI" id="10.1186/1752-0509-5-17"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2011" name="Sci. Signal." volume="4" first="RS3" last="RS3">
<title>System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.</title>
<authorList>
<person name="Rigbolt K.T."/>
<person name="Prokhorova T.A."/>
<person name="Akimov V."/>
<person name="Henningsen J."/>
<person name="Johansen P.T."/>
<person name="Kratchmarova I."/>
<person name="Kassem M."/>
<person name="Mann M."/>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
</authorList>
<dbReference type="PubMed" id="21406692"/>
<dbReference type="DOI" id="10.1126/scisignal.2001570"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-437</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-268; SER-435; SER-437; SER-727 AND SER-729</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="28">
<citation type="journal article" date="2016" name="Cell Chem. Biol." volume="23" first="1217" last="1227">
<title>Cyclooxygenase-2 Mediated Oxidation of 2-Arachidonoyl-Lysophospholipids Identifies Unknown Lipid Signaling Pathways.</title>
<authorList>
<person name="Liu X."/>
<person name="Moon S.H."/>
<person name="Jenkins C.M."/>
<person name="Sims H.F."/>
<person name="Gross R.W."/>
</authorList>
<dbReference type="PubMed" id="27642067"/>
<dbReference type="DOI" id="10.1016/j.chembiol.2016.08.009"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2017" name="Nat. Struct. Mol. Biol." volume="24" first="325" last="336">
<title>Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.</title>
<authorList>
<person name="Hendriks I.A."/>
<person name="Lyon D."/>
<person name="Young C."/>
<person name="Jensen L.J."/>
<person name="Vertegaal A.C."/>
<person name="Nielsen M.L."/>
</authorList>
<dbReference type="PubMed" id="28112733"/>
<dbReference type="DOI" id="10.1038/nsmb.3366"/>
</citation>
<scope>SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-541 AND LYS-606</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="30">
<citation type="journal article" date="1998" name="J. Biol. Chem." volume="273" first="1596" last="1604">
<title>Crystal structure of a calcium-phospholipid binding domain from cytosolic phospholipase A2.</title>
<authorList>
<person name="Perisic O."/>
<person name="Fong S."/>
<person name="Lynch D.E."/>
<person name="Bycroft M."/>
<person name="Williams R.L."/>
</authorList>
<dbReference type="PubMed" id="9430701"/>
<dbReference type="DOI" id="10.1074/jbc.273.3.1596"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 16-141 IN COMPLEX WITH CALCIUM IONS</scope>
<scope>DOMAIN</scope>
</reference>
<reference key="31">
<citation type="journal article" date="1998" name="J. Mol. Biol." volume="280" first="485" last="500">
<title>Solution structure and membrane interactions of the C2 domain of cytosolic phospholipase A2.</title>
<authorList>
<person name="Xu G.-Y."/>
<person name="McDonagh T."/>
<person name="Yu H.-A."/>
<person name="Nalefski E.A."/>
<person name="Clark J.D."/>
<person name="Cumming D.A."/>
</authorList>
<dbReference type="PubMed" id="9665851"/>
<dbReference type="DOI" id="10.1006/jmbi.1998.1874"/>
</citation>
<scope>STRUCTURE BY NMR OF 1-138 IN COMPLEX WITH CALCIUM IONS</scope>
<scope>DOMAIN</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="32">
<citation type="journal article" date="1999" name="Cell" volume="97" first="349" last="360">
<title>Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism.</title>
<authorList>
<person name="Dessen A."/>
<person name="Tang J."/>
<person name="Schmidt H."/>
<person name="Stahl M."/>
<person name="Clark J.D."/>
<person name="Seehra J."/>
<person name="Somers W.S."/>
</authorList>
<dbReference type="PubMed" id="10319815"/>
<dbReference type="DOI" id="10.1016/s0092-8674(00)80744-8"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH CALCIUM IONS</scope>
<scope>ACTIVE SITE</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2006" name="Science" volume="314" first="268" last="274">
<title>The consensus coding sequences of human breast and colorectal cancers.</title>
<authorList>
<person name="Sjoeblom T."/>
<person name="Jones S."/>
<person name="Wood L.D."/>
<person name="Parsons D.W."/>
<person name="Lin J."/>
<person name="Barber T.D."/>
<person name="Mandelker D."/>
<person name="Leary R.J."/>
<person name="Ptak J."/>
<person name="Silliman N."/>
<person name="Szabo S."/>
<person name="Buckhaults P."/>
<person name="Farrell C."/>
<person name="Meeh P."/>
<person name="Markowitz S.D."/>
<person name="Willis J."/>
<person name="Dawson D."/>
<person name="Willson J.K.V."/>
<person name="Gazdar A.F."/>
<person name="Hartigan J."/>
<person name="Wu L."/>
<person name="Liu C."/>
<person name="Parmigiani G."/>
<person name="Park B.H."/>
<person name="Bachman K.E."/>
<person name="Papadopoulos N."/>
<person name="Vogelstein B."/>
<person name="Kinzler K.W."/>
<person name="Velculescu V.E."/>
</authorList>
<dbReference type="PubMed" id="16959974"/>
<dbReference type="DOI" id="10.1126/science.1133427"/>
</citation>
<scope>VARIANT [LARGE SCALE ANALYSIS] GLN-442</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2008" name="J. Clin. Invest." volume="118" first="2121" last="2131">
<title>Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction.</title>
<authorList>
<person name="Adler D.H."/>
<person name="Cogan J.D."/>
<person name="Phillips J.A."/>
<person name="Schnetz-Boutaud N."/>
<person name="Milne G.L."/>
<person name="Iverson T."/>
<person name="Stein J.A."/>
<person name="Brenner D.A."/>
<person name="Morrow J.D."/>
<person name="Boutaud O."/>
<person name="Oates J.A."/>
</authorList>
<dbReference type="PubMed" id="18451993"/>
<dbReference type="DOI" id="10.1172/jci30473"/>
</citation>
<scope>INVOLVEMENT IN GURDP</scope>
<scope>VARIANTS GURDP PRO-111 AND HIS-485</scope>
<scope>VARIANT LYS-651</scope>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>PATHWAY</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2014" name="Gut" volume="63" first="96" last="104">
<title>Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-alpha.</title>
<authorList>
<person name="Brooke M.A."/>
<person name="Longhurst H.J."/>
<person name="Plagnol V."/>
<person name="Kirkby N.S."/>
<person name="Mitchell J.A."/>
<person name="Rueschendorf F."/>
<person name="Warner T.D."/>
<person name="Kelsell D.P."/>
<person name="MacDonald T.T."/>
</authorList>
<dbReference type="PubMed" id="23268370"/>
<dbReference type="DOI" id="10.1136/gutjnl-2012-303581"/>
</citation>
<scope>INVOLVEMENT IN GURDP</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2014" name="Thromb. Haemost." volume="112" first="1182" last="1189">
<title>Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency.</title>
<authorList>
<person name="Faioni E.M."/>
<person name="Razzari C."/>
<person name="Zulueta A."/>
<person name="Femia E.A."/>
<person name="Fenu L."/>
<person name="Trinchera M."/>
<person name="Podda G.M."/>
<person name="Pugliano M."/>
<person name="Marongiu F."/>
<person name="Cattaneo M."/>
</authorList>
<dbReference type="PubMed" id="25102815"/>
<dbReference type="DOI" id="10.1160/th14-04-0352"/>
</citation>
<scope>INVOLVEMENT IN GURDP</scope>
<scope>VARIANT GURDP HIS-575</scope>
<scope>CHARACTERIZATION OF VARIANT GURDP HIS-575</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<comment type="function">
<text evidence="10 15 18 19 21 23 24 29 30 33 34 35">Has primarily calcium-dependent phospholipase and lysophospholipase activities, with a major role in membrane lipid remodeling and biosynthesis of lipid mediators of the inflammatory response (PubMed:7794891, PubMed:8619991, PubMed:8702602, PubMed:9425121, PubMed:10358058, PubMed:14709560, PubMed:16617059, PubMed:17472963, PubMed:27642067, PubMed:18451993). Plays an important role in embryo implantation and parturition through its ability to trigger prostanoid production (By similarity). Preferentially hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) (PubMed:7794891, PubMed:8619991, PubMed:9425121, PubMed:10358058, PubMed:17472963, PubMed:18451993). Selectively hydrolyzes sn-2 arachidonoyl group from membrane phospholipids, providing the precursor for eicosanoid biosynthesis via the cyclooxygenase pathway (PubMed:18451993, PubMed:7794891, PubMed:9425121, PubMed:10358058, PubMed:17472963). In an alternative pathway of eicosanoid biosynthesis, hydrolyzes sn-2 fatty acyl chain of eicosanoid lysophopholipids to release free bioactive eicosanoids (PubMed:27642067). Hydrolyzes the ester bond of the fatty acyl group attached at sn-1 position of phospholipids (phospholipase A1 activity) only if an ether linkage rather than an ester linkage is present at the sn-2 position. This hydrolysis is not stereospecific (PubMed:7794891). Has calcium-independent phospholipase A2 and lysophospholipase activities in the presence of phosphoinositides (PubMed:12672805). Has O-acyltransferase activity. Catalyzes the transfer of fatty acyl chains from phospholipids to a primary hydroxyl group of glycerol (sn-1 or sn-3), potentially contributing to monoacylglycerol synthesis (PubMed:7794891).</text>
</comment>
<comment type="catalytic activity">
<reaction evidence="15 18 19 21 23 24 30 33 34">
<text>a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+)</text>
<dbReference type="Rhea" id="RHEA:15801"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:28868"/>
<dbReference type="ChEBI" id="CHEBI:57643"/>
<dbReference type="ChEBI" id="CHEBI:58168"/>
<dbReference type="EC" id="3.1.1.4"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="46">
<dbReference type="Rhea" id="RHEA:15802"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="18 21">
<text>a 1-acyl-sn-glycero-3-phosphocholine + H2O = a fatty acid + H(+) + sn-glycerol 3-phosphocholine</text>
<dbReference type="Rhea" id="RHEA:15177"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:16870"/>
<dbReference type="ChEBI" id="CHEBI:28868"/>
<dbReference type="ChEBI" id="CHEBI:58168"/>
<dbReference type="EC" id="3.1.1.5"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="42 44">
<dbReference type="Rhea" id="RHEA:15178"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="15 18 19 21 23 30">
<text>1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+)</text>
<dbReference type="Rhea" id="RHEA:40427"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:32395"/>
<dbReference type="ChEBI" id="CHEBI:72998"/>
<dbReference type="ChEBI" id="CHEBI:73003"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="42 45 48">
<dbReference type="Rhea" id="RHEA:40428"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="30">
<text>1,2-di-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine + H(+)</text>
<dbReference type="Rhea" id="RHEA:41075"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:32395"/>
<dbReference type="ChEBI" id="CHEBI:60657"/>
<dbReference type="ChEBI" id="CHEBI:74344"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="48">
<dbReference type="Rhea" id="RHEA:41076"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="24 30 35">
<text>1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-octadecanoyl-sn-glycero-3-phosphocholine + H(+)</text>
<dbReference type="Rhea" id="RHEA:40519"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:32395"/>
<dbReference type="ChEBI" id="CHEBI:73858"/>
<dbReference type="ChEBI" id="CHEBI:74965"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="46">
<dbReference type="Rhea" id="RHEA:40520"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="19">
<text>1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine + H2O = (9Z,12Z)-octadecadienoate + 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+)</text>
<dbReference type="Rhea" id="RHEA:40811"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:30245"/>
<dbReference type="ChEBI" id="CHEBI:72998"/>
<dbReference type="ChEBI" id="CHEBI:73002"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="43">
<dbReference type="Rhea" id="RHEA:40812"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="30">
<text>1-octadecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-sn-glycero-3-phosphocholine + H2O = (9Z,12Z,15Z)-octadecatrienoate + 1-octadecanoyl-sn-glycero-3-phosphocholine + H(+)</text>
<dbReference type="Rhea" id="RHEA:41307"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:32387"/>
<dbReference type="ChEBI" id="CHEBI:73858"/>
<dbReference type="ChEBI" id="CHEBI:78022"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="48">
<dbReference type="Rhea" id="RHEA:41308"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="30">
<text>1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-2-hexadecanoyl-sn-glycero-3-phosphocholine + H2O = 1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine + H(+) + hexadecanoate</text>
<dbReference type="Rhea" id="RHEA:41071"/>
<dbReference type="ChEBI" id="CHEBI:7896"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:74344"/>
<dbReference type="ChEBI" id="CHEBI:77694"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="48">
<dbReference type="Rhea" id="RHEA:41072"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="15 30">
<text>1-O-hexadecyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-O-hexadecyl-sn-glycero-3-phosphocholine + H(+)</text>
<dbReference type="Rhea" id="RHEA:41067"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:32395"/>
<dbReference type="ChEBI" id="CHEBI:55430"/>
<dbReference type="ChEBI" id="CHEBI:64496"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="41 48">
<dbReference type="Rhea" id="RHEA:41068"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="35">
<text>1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-sn-glycerol) + H2O = (9Z)-octadecenoate + 1-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-sn-glycerol) + H(+)</text>
<dbReference type="Rhea" id="RHEA:41123"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:30823"/>
<dbReference type="ChEBI" id="CHEBI:72828"/>
<dbReference type="ChEBI" id="CHEBI:75163"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="49">
<dbReference type="Rhea" id="RHEA:41124"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="35">
<text>1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphate + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-octadecanoyl-sn-glycero-3-phosphate + H(+)</text>
<dbReference type="Rhea" id="RHEA:40451"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:32395"/>
<dbReference type="ChEBI" id="CHEBI:74565"/>
<dbReference type="ChEBI" id="CHEBI:77091"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="49">
<dbReference type="Rhea" id="RHEA:40452"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="18 21">
<text>1-hexadecanoyl-sn-glycero-3-phosphocholine + H2O = H(+) + hexadecanoate + sn-glycerol 3-phosphocholine</text>
<dbReference type="Rhea" id="RHEA:40435"/>
<dbReference type="ChEBI" id="CHEBI:7896"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:16870"/>
<dbReference type="ChEBI" id="CHEBI:72998"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="42 44">
<dbReference type="Rhea" id="RHEA:40436"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="29">
<text>2-(prostaglandin E2)-sn-glycero-3-phosphoethanolamine + H2O = H(+) + prostaglandin E2 + sn-glycero-3-phosphoethanolamine</text>
<dbReference type="Rhea" id="RHEA:53704"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:137581"/>
<dbReference type="ChEBI" id="CHEBI:143890"/>
<dbReference type="ChEBI" id="CHEBI:606564"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="47">
<dbReference type="Rhea" id="RHEA:53705"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="29">
<text>2-[(15S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl]-sn-glycero-3-phosphocholine + H2O = (5Z,8Z,11Z,13E,15S)-hydroxyeicosatetraenoate + H(+) + sn-glycerol 3-phosphocholine</text>
<dbReference type="Rhea" id="RHEA:53700"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:16870"/>
<dbReference type="ChEBI" id="CHEBI:57409"/>
<dbReference type="ChEBI" id="CHEBI:137584"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="47">
<dbReference type="Rhea" id="RHEA:53701"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="29">
<text>2-[(15R)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl]-sn-glycero-3-phosphocholine + H2O = (15R)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoate + H(+) + sn-glycerol 3-phosphocholine</text>
<dbReference type="Rhea" id="RHEA:53696"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:16870"/>
<dbReference type="ChEBI" id="CHEBI:78837"/>
<dbReference type="ChEBI" id="CHEBI:137583"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="47">
<dbReference type="Rhea" id="RHEA:53697"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="29">
<text>2-(prostaglandin E2)-sn-glycero-3-phosphocholine + H2O = H(+) + prostaglandin E2 + sn-glycerol 3-phosphocholine</text>
<dbReference type="Rhea" id="RHEA:53692"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:16870"/>
<dbReference type="ChEBI" id="CHEBI:137585"/>
<dbReference type="ChEBI" id="CHEBI:606564"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="47">
<dbReference type="Rhea" id="RHEA:53693"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="29">
<text>2-[(11R)-hydroxy-(5Z,8Z,12E,14Z)-eicosatetraenoyl]-sn-glycero-3-phosphocholine + H2O = (11R)-hydroxy-(5Z,8Z,12E,14Z)-eicosatetraenoate + H(+) + sn-glycerol 3-phosphocholine</text>
<dbReference type="Rhea" id="RHEA:53688"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:16870"/>
<dbReference type="ChEBI" id="CHEBI:78836"/>
<dbReference type="ChEBI" id="CHEBI:137582"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="47">
<dbReference type="Rhea" id="RHEA:53689"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="30">
<text>1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-2-O-hexadecyl-sn-glycero-3-phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 2-O-hexadecyl-sn-glycero-3-phosphocholine + H(+)</text>
<dbReference type="Rhea" id="RHEA:41271"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:15378"/>
<dbReference type="ChEBI" id="CHEBI:32395"/>
<dbReference type="ChEBI" id="CHEBI:77695"/>
<dbReference type="ChEBI" id="CHEBI:77696"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="48">
<dbReference type="Rhea" id="RHEA:41272"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="30">
<text>1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine + glycerol = 1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycerol + 1-octadecanoyl-sn-glycero-3-phosphocholine</text>
<dbReference type="Rhea" id="RHEA:41099"/>
<dbReference type="ChEBI" id="CHEBI:17754"/>
<dbReference type="ChEBI" id="CHEBI:73858"/>
<dbReference type="ChEBI" id="CHEBI:74965"/>
<dbReference type="ChEBI" id="CHEBI:75612"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="48">
<dbReference type="Rhea" id="RHEA:41100"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="30">
<text>1-octadecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-sn-glycero-3-phosphocholine + glycerol = 1-(9Z,12Z,15Z-octadecatrienoyl)-glycerol + 1-octadecanoyl-sn-glycero-3-phosphocholine</text>
<dbReference type="Rhea" id="RHEA:41087"/>
<dbReference type="ChEBI" id="CHEBI:17754"/>
<dbReference type="ChEBI" id="CHEBI:73858"/>
<dbReference type="ChEBI" id="CHEBI:75610"/>
<dbReference type="ChEBI" id="CHEBI:78022"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="48">
<dbReference type="Rhea" id="RHEA:41088"/>
</physiologicalReaction>
</comment>
<comment type="activity regulation">
<text evidence="18 23 32 35">Activated by cytosolic calcium, which is necessary for binding to membrane lipids (PubMed:12672805). Activated by phosphorylation in response to mitogenic stimuli (PubMed:8381049). Activated by ceramide-1-phosphate. Binding (via C2 domain) to ceramide-1-phosphate increases the affinity for membrane lipids (PubMed:17472963). Can be activated by phosphoinositides in the absence of calcium (PubMed:12672805). Inhibited by ANXA5 in a calcium- and substrate-dependent way (PubMed:9425121).</text>
</comment>
<comment type="biophysicochemical properties">
<kinetics>
<Vmax evidence="31">2.7 umol/min/mg enzyme toward 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine (phospholipase A2 activity)</Vmax>
<Vmax evidence="31">4.6 umol/min/mg enzyme toward 1-hexadecanoyl-sn-glycero-3-phosphocholine (lysophospholipase activity)</Vmax>
<Vmax evidence="23">24.5 nmol/min/mg enzyme toward 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine (phospholipase A2 activity in the absence of ceramide-1-phosphate)</Vmax>
<Vmax evidence="23">240.5 nmol/min/mg enzyme toward 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine (phospholipase A2 activity, in the presence of ceramide-1-phosphate)</Vmax>
</kinetics>
</comment>
<comment type="pathway" evidence="10">
<text>Membrane lipid metabolism; glycerophospholipid metabolism.</text>
</comment>
<comment type="pathway" evidence="24">
<text>Lipid metabolism; arachidonate metabolism.</text>
</comment>
<comment type="pathway" evidence="24">
<text>Lipid metabolism; prostaglandin biosynthesis.</text>
</comment>
<comment type="pathway" evidence="24">
<text>Lipid metabolism; leukotriene B4 biosynthesis.</text>
</comment>
<comment type="subunit">
<text evidence="14 17 36 38">Interacts with KAT5.</text>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="16">Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="16">Golgi apparatus membrane</location>
</subcellularLocation>
<subcellularLocation>
<location>Nucleus envelope</location>
</subcellularLocation>
<text evidence="16">Translocates to intracellular membranes in a calcium-dependent way.</text>
</comment>
<comment type="tissue specificity">
<text evidence="28">Expressed in various cells and tissues such as macrophages, neutrophils, fibroblasts and lung endothelium. Expressed in platelets (at protein level) (PubMed:25102815).</text>
</comment>
<comment type="domain">
<text evidence="16 18 36 38">The N-terminal C2 domain associates with lipid membranes upon calcium binding. It modulates enzyme activity by presenting the active site to its substrate in response to elevations of cytosolic calcium (PubMed:9430701, PubMed:9665851, PubMed:11375391). In the presence of phosphoinositides, regulates phospholipase A2 and lysophospholipase activities in a calcium-independent way (PubMed:12672805).</text>
</comment>
<comment type="PTM">
<text evidence="32 37">Phosphorylated at both Ser-505 and Ser-727 in response to mitogenic stimuli.</text>
</comment>
<comment type="disease" evidence="24 27 28">
<disease id="DI-05517">
<name>Gastrointestinal ulceration, recurrent, with dysfunctional platelets</name>
<acronym>GURDP</acronym>
<description>An autosomal recessive disorder characterized by recurrent gastrointestinal mucosal ulcers, gastrointestinal bleeding, chronic anemia, iron deficiency, and abdominal pain. Disease features also include platelet dysfunction, and globally decreased eicosanoid synthesis.</description>
<dbReference type="MIM" id="618372"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="online information" name="NIEHS-SNPs">
<link uri="http://egp.gs.washington.edu/data/pla2g4a/"/>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/PLA2G4AID41733ch1q31.html"/>
</comment>
<dbReference type="EC" id="3.1.1.4" evidence="15 18 19 21 23 30"/>
<dbReference type="EC" id="3.1.1.5" evidence="18 21"/>
<dbReference type="EMBL" id="M72393">
<property type="protein sequence ID" value="AAB00789.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M68874">
<property type="protein sequence ID" value="AAA60105.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AY552098">
<property type="protein sequence ID" value="AAS45712.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AL022147">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AL049797">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC114340">
<property type="protein sequence ID" value="AAI14341.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS1372.1"/>
<dbReference type="PIR" id="A39329">
<property type="entry name" value="A39329"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001298122.1">
<property type="nucleotide sequence ID" value="NM_001311193.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_077734.1">
<property type="nucleotide sequence ID" value="NM_024420.2"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011507944.1">
<property type="nucleotide sequence ID" value="XM_011509642.2"/>
</dbReference>
<dbReference type="PDB" id="1BCI">
<property type="method" value="NMR"/>
<property type="chains" value="A=1-138"/>
</dbReference>
<dbReference type="PDB" id="1CJY">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A/B=1-749"/>
</dbReference>
<dbReference type="PDB" id="1RLW">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A=17-141"/>
</dbReference>
<dbReference type="PDBsum" id="1BCI"/>
<dbReference type="PDBsum" id="1CJY"/>
<dbReference type="PDBsum" id="1RLW"/>
<dbReference type="BMRB" id="P47712"/>
<dbReference type="SMR" id="P47712"/>
<dbReference type="BioGRID" id="111338">
<property type="interactions" value="36"/>
</dbReference>
<dbReference type="DIP" id="DIP-40991N"/>
<dbReference type="IntAct" id="P47712">
<property type="interactions" value="15"/>
</dbReference>
<dbReference type="MINT" id="P47712"/>
<dbReference type="STRING" id="9606.ENSP00000356436"/>
<dbReference type="BindingDB" id="P47712"/>
<dbReference type="ChEMBL" id="CHEMBL3816"/>
<dbReference type="DrugBank" id="DB00041">
<property type="generic name" value="Aldesleukin"/>
</dbReference>
<dbReference type="DrugBank" id="DB00411">
<property type="generic name" value="Carbamoylcholine"/>
</dbReference>
<dbReference type="DrugBank" id="DB00578">
<property type="generic name" value="Carbenicillin"/>
</dbReference>
<dbReference type="DrugBank" id="DB06311">
<property type="generic name" value="Darapladib"/>
</dbReference>
<dbReference type="DrugBank" id="DB00445">
<property type="generic name" value="Epirubicin"/>
</dbReference>
<dbReference type="DrugBank" id="DB13867">
<property type="generic name" value="Fluticasone"/>
</dbReference>
<dbReference type="DrugBank" id="DB00588">
<property type="generic name" value="Fluticasone propionate"/>
</dbReference>
<dbReference type="DrugBank" id="DB05029">
<property type="generic name" value="Lancovutide"/>
</dbReference>
<dbReference type="DrugBank" id="DB04552">
<property type="generic name" value="Niflumic acid"/>
</dbReference>
<dbReference type="DrugBank" id="DB01083">
<property type="generic name" value="Orlistat"/>
</dbReference>
<dbReference type="DrugBank" id="DB00721">
<property type="generic name" value="Procaine"/>
</dbReference>
<dbReference type="DrugBank" id="DB01103">
<property type="generic name" value="Quinacrine"/>
</dbReference>
<dbReference type="DrugBank" id="DB00086">
<property type="generic name" value="Streptokinase"/>
</dbReference>
<dbReference type="DrugBank" id="DB04786">
<property type="generic name" value="Suramin"/>
</dbReference>
<dbReference type="DrugBank" id="DB04827">
<property type="generic name" value="Urethane"/>
</dbReference>
<dbReference type="DrugCentral" id="P47712"/>
<dbReference type="GuidetoPHARMACOLOGY" id="1424"/>
<dbReference type="SwissLipids" id="SLP:000000565"/>
<dbReference type="iPTMnet" id="P47712"/>
<dbReference type="MetOSite" id="P47712"/>
<dbReference type="PhosphoSitePlus" id="P47712"/>
<dbReference type="BioMuta" id="PLA2G4A"/>
<dbReference type="DMDM" id="317373312"/>
<dbReference type="EPD" id="P47712"/>
<dbReference type="jPOST" id="P47712"/>
<dbReference type="MassIVE" id="P47712"/>
<dbReference type="MaxQB" id="P47712"/>
<dbReference type="PaxDb" id="P47712"/>
<dbReference type="PeptideAtlas" id="P47712"/>
<dbReference type="PRIDE" id="P47712"/>
<dbReference type="ProteomicsDB" id="55788"/>
<dbReference type="Antibodypedia" id="4104">
<property type="antibodies" value="378 antibodies"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000367466">
<property type="protein sequence ID" value="ENSP00000356436"/>
<property type="gene ID" value="ENSG00000116711"/>
</dbReference>
<dbReference type="GeneID" id="5321"/>
<dbReference type="KEGG" id="hsa:5321"/>
<dbReference type="UCSC" id="uc001gsc.4">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="5321"/>
<dbReference type="DisGeNET" id="5321"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000116711.9"/>
<dbReference type="GeneCards" id="PLA2G4A"/>
<dbReference type="HGNC" id="HGNC:9035">
<property type="gene designation" value="PLA2G4A"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000116711">
<property type="expression patterns" value="Tissue enhanced (ductus deferens, parathyroid gland, seminal vesicle)"/>
</dbReference>
<dbReference type="MalaCards" id="PLA2G4A"/>
<dbReference type="MIM" id="600522">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="618372">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P47712"/>
<dbReference type="OpenTargets" id="ENSG00000116711"/>
<dbReference type="Orphanet" id="468635">
<property type="disease" value="Cryptogenic multifocal ulcerous stenosing enteritis"/>
</dbReference>
<dbReference type="Orphanet" id="477787">
<property type="disease" value="Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder"/>
</dbReference>
<dbReference type="PharmGKB" id="PA271"/>
<dbReference type="eggNOG" id="KOG1012">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="KOG1325">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT01000000214502"/>
<dbReference type="HOGENOM" id="CLU_011663_1_1_1"/>
<dbReference type="InParanoid" id="P47712"/>
<dbReference type="KO" id="K16342"/>
<dbReference type="OMA" id="DPYQHIV"/>
<dbReference type="OrthoDB" id="302848at2759"/>
<dbReference type="PhylomeDB" id="P47712"/>
<dbReference type="TreeFam" id="TF325228"/>
<dbReference type="BioCyc" id="MetaCyc:HS04039-MONOMER"/>
<dbReference type="BRENDA" id="3.1.1.4">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="PathwayCommons" id="P47712"/>
<dbReference type="Reactome" id="R-HSA-111995">
<property type="pathway name" value="phospho-PLA2 pathway"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1482788">
<property type="pathway name" value="Acyl chain remodelling of PC"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1482798">
<property type="pathway name" value="Acyl chain remodeling of CL"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1482801">
<property type="pathway name" value="Acyl chain remodelling of PS"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1482839">
<property type="pathway name" value="Acyl chain remodelling of PE"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1482922">
<property type="pathway name" value="Acyl chain remodelling of PI"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1482925">
<property type="pathway name" value="Acyl chain remodelling of PG"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1483115">
<property type="pathway name" value="Hydrolysis of LPC"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1483166">
<property type="pathway name" value="Synthesis of PA"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2142753">
<property type="pathway name" value="Arachidonic acid metabolism"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-418592">
<property type="pathway name" value="ADP signalling through P2Y purinoceptor 1"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-432142">
<property type="pathway name" value="Platelet sensitization by LDL"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6811436">
<property type="pathway name" value="COPI-independent Golgi-to-ER retrograde traffic"/>
</dbReference>
<dbReference type="SIGNOR" id="P47712"/>
<dbReference type="UniPathway" id="UPA00383"/>
<dbReference type="UniPathway" id="UPA00662"/>
<dbReference type="UniPathway" id="UPA00878"/>
<dbReference type="UniPathway" id="UPA00940"/>
<dbReference type="BioGRID-ORCS" id="5321">
<property type="hits" value="4 hits in 874 CRISPR screens"/>
</dbReference>
<dbReference type="ChiTaRS" id="PLA2G4A">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P47712"/>
<dbReference type="GeneWiki" id="PLA2G4A"/>
<dbReference type="GenomeRNAi" id="5321"/>
<dbReference type="Pharos" id="P47712">
<property type="development level" value="Tchem"/>
</dbReference>
<dbReference type="PRO" id="PR:P47712"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 1"/>
</dbReference>
<dbReference type="RNAct" id="P47712">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000116711">
<property type="expression patterns" value="Expressed in seminal vesicle and 203 other tissues"/>
</dbReference>
<dbReference type="Genevisible" id="P47712">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005737">
<property type="term" value="C:cytoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0005783">
<property type="term" value="C:endoplasmic reticulum"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0005789">
<property type="term" value="C:endoplasmic reticulum membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005794">
<property type="term" value="C:Golgi apparatus"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0000139">
<property type="term" value="C:Golgi membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005811">
<property type="term" value="C:lipid droplet"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0005743">
<property type="term" value="C:mitochondrial inner membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005635">
<property type="term" value="C:nuclear envelope"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0005509">
<property type="term" value="F:calcium ion binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0047498">
<property type="term" value="F:calcium-dependent phospholipase A2 activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005544">
<property type="term" value="F:calcium-dependent phospholipid binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0047499">
<property type="term" value="F:calcium-independent phospholipase A2 activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1902387">
<property type="term" value="F:ceramide 1-phosphate binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004622">
<property type="term" value="F:lysophospholipase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008374">
<property type="term" value="F:O-acyltransferase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0102545">
<property type="term" value="F:phosphatidyl phospholipase B activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-EC"/>
</dbReference>
<dbReference type="GO" id="GO:0032266">
<property type="term" value="F:phosphatidylinositol-3-phosphate binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070273">
<property type="term" value="F:phosphatidylinositol-4-phosphate binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010314">
<property type="term" value="F:phosphatidylinositol-5-phosphate binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004623">
<property type="term" value="F:phospholipase A2 activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0102567">
<property type="term" value="F:phospholipase A2 activity (consuming 1,2-dipalmitoylphosphatidylcholine)"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-EC"/>
</dbReference>
<dbReference type="GO" id="GO:0102568">
<property type="term" value="F:phospholipase A2 activity consuming 1,2-dioleoylphosphatidylethanolamine)"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-EC"/>
</dbReference>
<dbReference type="GO" id="GO:0019369">
<property type="term" value="P:arachidonic acid metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050482">
<property type="term" value="P:arachidonic acid secretion"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0035965">
<property type="term" value="P:cardiolipin acyl-chain remodeling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0071236">
<property type="term" value="P:cellular response to antibiotic"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006071">
<property type="term" value="P:glycerol metabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0046475">
<property type="term" value="P:glycerophospholipid catabolic process"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0006690">
<property type="term" value="P:icosanoid metabolic process"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0019370">
<property type="term" value="P:leukotriene biosynthetic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006640">
<property type="term" value="P:monoacylglycerol biosynthetic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006654">
<property type="term" value="P:phosphatidic acid biosynthetic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0036151">
<property type="term" value="P:phosphatidylcholine acyl-chain remodeling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0034638">
<property type="term" value="P:phosphatidylcholine catabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0036152">
<property type="term" value="P:phosphatidylethanolamine acyl-chain remodeling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0036148">
<property type="term" value="P:phosphatidylglycerol acyl-chain remodeling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0034478">
<property type="term" value="P:phosphatidylglycerol catabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0036149">
<property type="term" value="P:phosphatidylinositol acyl-chain remodeling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0036150">
<property type="term" value="P:phosphatidylserine acyl-chain remodeling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0006644">
<property type="term" value="P:phospholipid metabolic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0006663">
<property type="term" value="P:platelet activating factor biosynthetic process"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043032">
<property type="term" value="P:positive regulation of macrophage activation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0010572">
<property type="term" value="P:positive regulation of platelet activation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032308">
<property type="term" value="P:positive regulation of prostaglandin secretion"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0002827">
<property type="term" value="P:positive regulation of T-helper 1 type immune response"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001516">
<property type="term" value="P:prostaglandin biosynthetic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042127">
<property type="term" value="P:regulation of cell population proliferation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="CDD" id="cd04036">
<property type="entry name" value="C2_cPLA2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.150">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR016035">
<property type="entry name" value="Acyl_Trfase/lysoPLipase"/>
</dbReference>
<dbReference type="InterPro" id="IPR041847">
<property type="entry name" value="C2_cPLA2"/>
</dbReference>
<dbReference type="InterPro" id="IPR000008">
<property type="entry name" value="C2_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR035892">
<property type="entry name" value="C2_domain_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR002642">
<property type="entry name" value="LysoPLipase_cat_dom"/>
</dbReference>
<dbReference type="Pfam" id="PF00168">
<property type="entry name" value="C2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF01735">
<property type="entry name" value="PLA2_B"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00239">
<property type="entry name" value="C2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00022">
<property type="entry name" value="PLAc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF52151">
<property type="entry name" value="SSF52151"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50004">
<property type="entry name" value="C2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS51210">
<property type="entry name" value="PLA2C"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0106">Calcium</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0903">Direct protein sequencing</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0275">Fatty acid biosynthesis</keyword>
<keyword id="KW-0276">Fatty acid metabolism</keyword>
<keyword id="KW-0319">Glycerol metabolism</keyword>
<keyword id="KW-0333">Golgi apparatus</keyword>
<keyword id="KW-0378">Hydrolase</keyword>
<keyword id="KW-1017">Isopeptide bond</keyword>
<keyword id="KW-0434">Leukotriene biosynthesis</keyword>
<keyword id="KW-0444">Lipid biosynthesis</keyword>
<keyword id="KW-0442">Lipid degradation</keyword>
<keyword id="KW-0443">Lipid metabolism</keyword>
<keyword id="KW-0446">Lipid-binding</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0479">Metal-binding</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0595">Phospholipid degradation</keyword>
<keyword id="KW-1208">Phospholipid metabolism</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0643">Prostaglandin biosynthesis</keyword>
<keyword id="KW-0644">Prostaglandin metabolism</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<feature type="chain" description="Cytosolic phospholipase A2" id="PRO_0000187262">
<location>
<begin position="1"/>
<end position="749"/>
</location>
</feature>
<feature type="domain" description="C2" evidence="12">
<location>
<begin position="6"/>
<end position="122"/>
</location>
</feature>
<feature type="domain" description="PLA2c" evidence="13">
<location>
<begin position="140"/>
<end position="740"/>
</location>
</feature>
<feature type="region of interest" description="Phospholipid binding" evidence="40">
<location>
<begin position="1"/>
<end position="178"/>
</location>
</feature>
<feature type="active site" description="Nucleophile" evidence="14 31 33 34">
<location>
<position position="228"/>
</location>
</feature>
<feature type="active site" description="Proton acceptor" evidence="14 34">
<location>
<position position="549"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Calcium 1">
<location>
<position position="40"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Calcium 2">
<location>
<position position="40"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Calcium 1; via carbonyl oxygen">
<location>
<position position="41"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Calcium 1">
<location>
<position position="43"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Calcium 2">
<location>
<position position="43"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Calcium 1">
<location>
<position position="65"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Calcium 2">
<location>
<position position="93"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Calcium 2; via carbonyl oxygen">
<location>
<position position="94"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Calcium 2">
<location>
<position position="95"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="8">
<location>
<position position="2"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine" evidence="5 6 8">
<location>
<position position="268"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="11">
<location>
<position position="434"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="8">
<location>
<position position="435"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5 6 7 8">
<location>
<position position="437"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by MAPK" evidence="32 37">
<location>
<position position="505"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="11">
<location>
<position position="515"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5 8 37">
<location>
<position position="727"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="4 5 6 8">
<location>
<position position="729"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="9">
<location>
<position position="541"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="9">
<location>
<position position="606"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs28395828." id="VAR_029276">
<original>G</original>
<variation>R</variation>
<location>
<position position="103"/>
</location>
</feature>
<feature type="sequence variant" description="In GURDP; unknown pathological significance; found in a compound heterozygote also carrying H-485; dbSNP:rs121434634." id="VAR_070778" evidence="24">
<original>S</original>
<variation>P</variation>
<location>
<position position="111"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs12720588." id="VAR_018760" evidence="39">
<original>V</original>
<variation>I</variation>
<location>
<position position="224"/>
</location>
</feature>
<feature type="sequence variant" description="In a breast cancer sample; somatic mutation; dbSNP:rs370896190." id="VAR_035826" evidence="22">
<original>H</original>
<variation>Q</variation>
<location>
<position position="442"/>
</location>
</feature>
<feature type="sequence variant" description="In GURDP; unknown pathological significance; found in a compound heterozygote also carrying P-111; dbSNP:rs121434635." id="VAR_070779" evidence="24">
<original>R</original>
<variation>H</variation>
<location>
<position position="485"/>
</location>
</feature>
<feature type="sequence variant" description="In GURDP; decreased protein expression, if any, in platelets from homozygous patients; dbSNP:rs1557895416." id="VAR_082091" evidence="28">
<original>D</original>
<variation>H</variation>
<location>
<position position="575"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs28395831." id="VAR_062128">
<original>I</original>
<variation>V</variation>
<location>
<position position="637"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs2307198." id="VAR_018424" evidence="20 24 25 26 39">
<original>R</original>
<variation>K</variation>
<location>
<position position="651"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs phospholipase A2 and lysophospholipase activities in the absence of phosphoinositides. Has full activity in the presence of phosphoinositides." evidence="18">
<original>D</original>
<variation>N</variation>
<location>
<position position="43"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs binding to ceramide-1-phosphate." evidence="23">
<original>RKR</original>
<variation>AAA</variation>
<location>
<begin position="57"/>
<end position="59"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phospholipase activity; when associated with A-141 and A-151." evidence="31">
<original>C</original>
<variation>A</variation>
<location>
<position position="139"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phospholipase activity; when associated with A-139 and A-151." evidence="31">
<original>C</original>
<variation>A</variation>
<location>
<position position="141"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phospholipase activity; when associated with A-139 and A-141." evidence="31">
<original>C</original>
<variation>A</variation>
<location>
<position position="151"/>
</location>
</feature>
<feature type="mutagenesis site" description="5-fold reduced phospholipase and lysophospholipase activities. 100-fold reduced phospholipase and lysophospholipase activities; when associated with A-577." evidence="31">
<original>S</original>
<variation>A</variation>
<location>
<position position="195"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes phospholipase activity." evidence="34">
<original>R</original>
<variation>A</variation>
<variation>H</variation>
<location>
<position position="200"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces phospholipase activity 200-fold." evidence="34">
<original>R</original>
<variation>K</variation>
<location>
<position position="200"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phospholipase or lysophospholipase activity." evidence="31">
<original>S</original>
<variation>A</variation>
<location>
<position position="215"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phospholipase activity." evidence="31">
<original>C</original>
<variation>A</variation>
<location>
<position position="220"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes both phospholipase and lysophospholipase activities." evidence="31 33 34">
<original>S</original>
<variation>A</variation>
<variation>C</variation>
<variation>T</variation>
<location>
<position position="228"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phospholipase activity; when associated with A-331." evidence="31">
<original>C</original>
<variation>A</variation>
<location>
<position position="324"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phospholipase activity; when associated with A-324." evidence="31">
<original>C</original>
<variation>A</variation>
<location>
<position position="331"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces phospholipase A2 activity; when associated with A-454; A-505 and A-727." evidence="18">
<original>S</original>
<variation>A</variation>
<location>
<position position="437"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces phospholipase A2 activity; when associated with A-437; A-505 and A-727." evidence="18">
<original>S</original>
<variation>A</variation>
<location>
<position position="454"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs phosphoinositide-stimulated phospholipase A2 activity." evidence="18">
<original>K</original>
<variation>E</variation>
<location>
<position position="488"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreases agonist-stimulated release of arachidonic acid. Reduces phospholipase A2 activity; when associated with A-437; A-454 and A-727." evidence="18 32">
<original>S</original>
<variation>A</variation>
<location>
<position position="505"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs phosphoinositide-stimulated phospholipase A2 activity; when associated with A-543 and A-544." evidence="18">
<original>K</original>
<variation>A</variation>
<location>
<position position="541"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs phosphoinositide-stimulated phospholipase A2 activity.; when associated with A-541 and A-544." evidence="18">
<original>K</original>
<variation>A</variation>
<location>
<position position="543"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs phosphoinositide-stimulated phospholipase A2 activity.; when associated with A-541 and A-543." evidence="18">
<original>K</original>
<variation>A</variation>
<location>
<position position="544"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes phospholipiase activity." evidence="34">
<original>D</original>
<variation>A</variation>
<location>
<position position="549"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces phospholipase activity 2000-fold." evidence="34">
<original>D</original>
<variation>E</variation>
<location>
<position position="549"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces phospholipase activity 300-fold." evidence="34">
<original>D</original>
<variation>N</variation>
<location>
<position position="549"/>
</location>
</feature>
<feature type="mutagenesis site" description="7-fold reduced phospholipase and lysophospholipase activities. 100-fold reduced phospholipase and lysophospholipase activities; when associated with A-195." evidence="31">
<original>S</original>
<variation>A</variation>
<location>
<position position="577"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phospholipase activity; when associated with A-634." evidence="31">
<original>C</original>
<variation>A</variation>
<location>
<position position="620"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phospholipase activity; when associated with A-620." evidence="31">
<original>C</original>
<variation>A</variation>
<location>
<position position="634"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phospholipase activity." evidence="31">
<original>C</original>
<variation>A</variation>
<location>
<position position="726"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces phospholipase A2 activity; when associated with A-437; A-455 and A-505." evidence="18">
<original>S</original>
<variation>A</variation>
<location>
<position position="727"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="18"/>
<end position="29"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="34"/>
<end position="39"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="44"/>
<end position="49"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="51"/>
<end position="54"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="57"/>
<end position="60"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="70"/>
<end position="79"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="86"/>
<end position="93"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="96"/>
<end position="98"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="100"/>
<end position="108"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="109"/>
<end position="111"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="117"/>
<end position="124"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="125"/>
<end position="127"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="128"/>
<end position="137"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="143"/>
<end position="146"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="152"/>
<end position="177"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="179"/>
<end position="181"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="190"/>
<end position="194"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="198"/>
<end position="214"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="218"/>
<end position="220"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="221"/>
<end position="226"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="228"/>
<end position="239"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="241"/>
<end position="245"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="248"/>
<end position="260"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="263"/>
<end position="266"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="269"/>
<end position="284"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="291"/>
<end position="304"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="305"/>
<end position="307"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="313"/>
<end position="318"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="319"/>
<end position="321"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="326"/>
<end position="333"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="341"/>
<end position="343"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="344"/>
<end position="349"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="354"/>
<end position="356"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="357"/>
<end position="360"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="361"/>
<end position="363"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="365"/>
<end position="367"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="370"/>
<end position="373"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="376"/>
<end position="379"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="386"/>
<end position="393"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="396"/>
<end position="399"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="401"/>
<end position="404"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="417"/>
<end position="423"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="426"/>
<end position="429"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="463"/>
<end position="476"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="488"/>
<end position="490"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="492"/>
<end position="495"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="543"/>
<end position="548"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="550"/>
<end position="552"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="558"/>
<end position="561"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="564"/>
<end position="566"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="570"/>
<end position="575"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="588"/>
<end position="599"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="611"/>
<end position="615"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="619"/>
<end position="623"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="636"/>
<end position="641"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="646"/>
<end position="648"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="650"/>
<end position="652"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="660"/>
<end position="666"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="670"/>
<end position="672"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="687"/>
<end position="702"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="705"/>
<end position="718"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1BCI"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1CJY"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1RLW"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="16964243"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="18669648"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="20068231"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="21406692"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="28112733"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P47713"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P50393"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00041"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00555"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10319815"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10358058"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11375391"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11416127"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12672805"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14709560"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16617059"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16959974"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17472963"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18451993"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1869522"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1904318"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23268370"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25102815"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27642067"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7794891"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8083230"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8381049"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8619991"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8702602"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9425121"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9430701"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9468497"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9665851"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source ref="3"/>
</evidence>
<evidence key="40" type="ECO:0000305"/>
<evidence key="41" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="10358058"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="12672805"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="14709560"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="16617059"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="17472963"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="18451993"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="27642067"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="7794891"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="9425121"/>
</source>
</evidence>
<sequence length="749" mass="85239" checksum="EE71CA0EBE617856" modified="2011-01-11" version="2">MSFIDPYQHIIVEHQYSHKFTVVVLRATKVTKGAFGDMLDTPDPYVELFISTTPDSRKRTRHFNNDINPVWNETFEFILDPNQENVLEITLMDANYVMDETLGTATFTVSSMKVGEKKEVPFIFNQVTEMVLEMSLEVCSCPDLRFSMALCDQEKTFRQQRKEHIRESMKKLLGPKNSEGLHSARDVPVVAILGSGGGFRAMVGFSGVMKALYESGILDCATYVAGLSGSTWYMSTLYSHPDFPEKGPEEINEELMKNVSHNPLLLLTPQKVKRYVESLWKKKSSGQPVTFTDIFGMLIGETLIHNRMNTTLSSLKEKVNTAQCPLPLFTCLHVKPDVSELMFADWVEFSPYEIGMAKYGTFMAPDLFGSKFFMGTVVKKYEENPLHFLMGVWGSAFSILFNRVLGVSGSQSRGSTMEEELENITTKHIVSNDSSDSDDESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFNTREGRAGKVHNFMLGLNLNTSYPLSPLSDFATQDSFDDDELDAAVADPDEFERIYEPLDVKSKKIHVVDSGLTFNLPYPLILRPQRGVDLIISFDFSARPSDSSPPFKELLLAEKWAKMNKLPFPKIDPYVFDREGLKECYVFKPKNPDMEKDCPTIIHFVLANINFRKYRAPGVPRETEEEKEIADFDIFDDPESPFSTFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRRQNPSRCSVSLSNVEARRFFNKEFLSKPKA</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>

